Analyst Ratings February 11, 2026

BMO Lifts Marriott Price Target to $400, Citing Strong 2026 Profit Outlook

Analyst upgrade reflects upside to EBITDA and EPS driven by net unit growth and higher credit-card fees

By Ajmal Hussain MAR
BMO Lifts Marriott Price Target to $400, Citing Strong 2026 Profit Outlook
MAR

BMO Capital Markets raised its price target on Marriott International to $400 from $370 and kept an Outperform rating after management outlined a stronger 2026 outlook. The firm highlighted upside to EBITDA and EPS driven by better-than-expected net unit growth and a lift in credit-card-related fees. Recent quarterly results showed mixed signals - an EPS slight miss but revenue and adjusted EBITDA ahead of estimates - prompting several other analysts to raise targets as well.

Key Points

  • BMO Capital Markets raised Marriott's price target to $400 from $370 and kept an Outperform rating, citing upside to EBITDA and EPS.
  • Management guided to 4.5%-5.0% net unit growth, supported by conversion activity and a 15% increase in the under-construction pipeline.
  • A higher royalty rate is expected to produce a 35% rise in credit-card fees, with renegotiations offering potential incremental upside.

BMO Capital Markets raised its target price for Marriott International (NASDAQ:MAR) to $400.00 from $370.00 and reiterated an Outperform rating on the hotel operator's shares. The firm pointed to a stronger-than-expected 2026 outlook that leaves room for upside to both EBITDA and earnings per share, while citing two operational drivers in particular: net unit growth and increased credit-card fees.

Shares of Marriott have moved sharply higher in recent trading, climbing 10.72% over the past week and trading close to their 52-week high, according to InvestingPro data. Despite that recent rally, InvestingPro's Fair Value model still indicates the company appears undervalued.

BMO said net unit growth - a key investor concern heading into the results - looks healthier than anticipated. Management's guidance calls for 4.5% to 5.0% net unit growth for the period referenced, an acceleration versus 2025, supported by robust conversion activity and a 15% expansion in properties currently under construction. The research note framed that trajectory as a pickup in franchise and conversion momentum that contributes to the firm's expectation for higher EBITDA and EPS.

The firm also flagged fee-related dynamics as material to the outlook. A higher royalty rate is expected to be a primary driver behind a forecasted 35% jump in credit-card fees. BMO noted upcoming renegotiations tied to co-branded card programs could provide incremental upside beyond that projection.

InvestingPro data referenced by BMO underscores Marriott's strong operating efficiency, showing gross profit margins of 94.45%. InvestingPro additionally lists 17 further investment insights for Marriott in its Pro Research Report.

While BMO acknowledged that demand fundamentals across the broader hospitality sector remain mixed, the firm said Marriott's upper-end portfolio appears relatively well-positioned in the current market. The company currently trades at a price-to-earnings ratio of 34.83, a multiple that reflects investor willingness to pay for its premium positioning despite the elevated valuation.

Marriott's reported fourth-quarter 2025 results contained both upside and a slight miss relative to consensus. The company posted adjusted EBITDA of $1,402 million, beating the Street expectation of $1,390 million and topping the company's own guidance range. Revenue for the quarter was $6.69 billion, above the $6.67 billion analysts had anticipated. On the profitability side, reported EPS came in at $2.58, a slight miss versus the $2.61 consensus.

Following those results, several sell-side analysts adjusted their targets higher. Barclays lifted its price target to $356, attributing the change in part to an unexpected increase in the royalty rate from Marriott's co-branded credit card program. BofA Securities raised its target to $395 and maintained a Buy rating after the EBITDA outperformance. Stifel also moved its target up to $333, citing the company's EBITDA performance as a key driver. These revisions reflect a broadly constructive response from analysts despite the modest EPS shortfall.


What this means for markets and investors

  • Analyst confidence in Marriott's near-term profit trajectory is rising, driven by unit growth and fee recoveries that directly affect EBITDA and EPS.
  • The stock's premium multiple and proximity to 52-week highs indicate investor appetite for higher-end hospitality exposure, even as sector demand varies.
  • Credit-card program economics - including royalty rates and renegotiation outcomes - are a material earnings lever for the company.

Context and limitations

While the estimates and commentary from BMO and other firms point to potential upside, the company did record a slight EPS miss in the quarter, underscoring that results can contain offsetting signals. The market's reaction and subsequent analyst revisions also show how sensitive valuation is to fee structures and unit growth assumptions.

Risks

  • Underlying demand fundamentals in the hospitality sector are mixed, which could pressure occupancy and room-rate recovery across segments - affecting hotel companies and travel-related markets.
  • Marriott reported an EPS miss in the quarter (EPS $2.58 vs. expected $2.61), indicating profit metrics can be volatile even when revenue and EBITDA beat expectations - a risk for equity valuations in the hotel sector.
  • Credit-card royalty rates and the outcomes of renegotiations are a significant earnings lever; unfavorable terms could reduce projected fee growth and impact financial results.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026